Selected article for: "antiviral spectrum and MERS cov"
Author: Kumar, Vathan; Shin, Jin Soo; Shie, Jiun-Jie; Ku, Keun Bon; Kim, Chonsaeng; Go, Yun Young; Huang, Kai-Fa; Kim, Meehyein; Liang, Po-Huang
Title: Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors
  • Cord-id: wr10ar5p
  • Document date: 2017_2_17
    • ID: wr10ar5p
    Snippet: Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe acute respiratory illness with fever, cough and shortness of breath. Up to date, it has resulted in 1826 human infections, including 649 deaths. Analogous to picornavirus 3C protease (3C(pro)), 3C-like protease (3CL(pro)) is critical for initiation of the MERS-CoV replication cycle and is thus regarded as a validated drug target. As presented here, our peptidomimetic inhibitors of enterovirus 3C(pro) (6b, 6c and 6d) inhibited
    Document: Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe acute respiratory illness with fever, cough and shortness of breath. Up to date, it has resulted in 1826 human infections, including 649 deaths. Analogous to picornavirus 3C protease (3C(pro)), 3C-like protease (3CL(pro)) is critical for initiation of the MERS-CoV replication cycle and is thus regarded as a validated drug target. As presented here, our peptidomimetic inhibitors of enterovirus 3C(pro) (6b, 6c and 6d) inhibited 3CL(pro) of MERS-CoV and severe acute respiratory syndrome coronavirus (SARS-CoV) with IC(50) values ranging from 1.7 to 4.7 μM and from 0.2 to 0.7 μM, respectively. In MERS-CoV-infected cells, the inhibitors showed antiviral activity with EC(50) values ranging from 0.6 to 1.4 μM, by downregulating the viral protein production in cells as well as reducing secretion of infectious viral particles into culture supernatants. They also suppressed other α- and β-CoVs from human and feline origin. These compounds exhibited good selectivity index (over 70 against MERS-CoV) and could lead to the development of broad-spectrum antiviral drugs against emerging CoVs and picornaviruses.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute sars cov respiratory syndrome cov: 1, 2, 3
    • absence presence and loading control: 1, 2, 3
    • absence presence and lysis buffer: 1, 2, 3, 4, 5
    • actin loading control and loading control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • actin loading control and lysis buffer: 1, 2
    • actin specific and loading control: 1
    • active site and acute sars cov respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and loading control: 1
    • activity critical and acute sars cov respiratory syndrome cov: 1, 2